Targeting tumor-intrinsic SLC16A3 to enhance anti-PD-1 efficacy via tumor immune microenvironment reprogramming
To study the impacts of glycolytic states of tumor cells, we took advantage of different in vitro culture systems and established demanded glycolysis states in B16F10 cells. B16F10 cells were maintained with either RPMI-1640 or DMEM mediums to maintain different metabolic models. Overall design: Comparative gene expression profiling analysis of RNA-seq data for B16F10 cells treated in DMEM or RPMI-1640.